Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia Polycythemia Vera Myelofibrosis

被引：14

作者：

Verstovsek, Srdan ^{[1
]}

Odenike, Olatoyosi ^{[2
]}

Scott, Bart ^{[3
]}

Estrov, Zeev ^{[1
]}

Cortes, Jorge ^{[1
]}

Thomas, Deborah A. ^{[1
]}

Wood, Jeanette ^{[4
]}

Ethirajulu, Kantharaj ^{[4
]}

Lowe, Ann ^{[4
]}

Zhu, Huan J. ^{[4
]}

Kantarjian, Hagop ^{[1
]}

Deeg, H. Joachim ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[4] S BIO PTE LTD, Singapore, Singapore

来源：

关键词：

D O I：

10.1182/blood.V114.22.3905.3905

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1502 / 1502

页数：1